![](https://investorshub.advfn.com/uicon/48355.png?cb=1551739062)
Wednesday, August 25, 2021 5:19:58 PM
3:46 pm ET August 25, 2021
By Stephen Nakrosis
Ascendis Pharma A/S on Wednesday said the U.S. Food and Drug Administration approved its Skytrofa as a treatment for Pediatric Growth Hormone Deficiency.
The company said Skytrofa, or lonapegsomatropin-tcgd, is the first once-weekly treatment approved to treat Pediatric Growth Hormone Deficiency.
The company also said Skytrofa was approved to treat "pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone."
The company said the approval includes its Skytrofa Auto-Injector and cartridges, which enable families to store the medicine at room temperature for up to six months.
The company said availability of Skytrofa in the U.S. is expected soon.
Ascendis said it would hold an investor conference call at 4:30 p.m. ET today.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
New York Yankees and Duke Basketball
Recent ASND News
- Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024 • GlobeNewswire Inc. • 06/24/2024 08:45:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/12/2024 08:01:51 PM
- Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 08:01:00 PM
- Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024 • GlobeNewswire Inc. • 06/03/2024 08:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/31/2024 08:26:57 PM
- Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024 • GlobeNewswire Inc. • 05/30/2024 12:30:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/29/2024 08:08:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/16/2024 08:01:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/14/2024 06:37:58 PM
- Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism • GlobeNewswire Inc. • 05/14/2024 06:31:44 PM
- Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial • GlobeNewswire Inc. • 05/13/2024 12:30:00 PM
- Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024 • GlobeNewswire Inc. • 05/09/2024 12:30:00 PM
- Ascendis Pharma Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/02/2024 08:01:00 PM
- Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024 • GlobeNewswire Inc. • 04/25/2024 08:46:31 PM
- United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism • GlobeNewswire Inc. • 04/24/2024 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/07/2024 04:31:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 02:39:29 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 01:14:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 01:04:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 12:37:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 08:17:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 08:07:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 07:54:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 07:36:16 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM